Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma

Radiographics

Volumn 35, Issue 3, 2015, Pages 747-764

  Toledano Massiah, Sarah ^a   Luciani, Alain ^a,b   Itti, Emmanuel ^a,b   Zerbib, Pierre ^a   Vignaud, Alexandre ^c   Belhadj, Karim ^a   Baranes, Laurence ^a,b   Haioun, Corinne ^a,b   Lin, Chieh ^d   Rahmouni, Alain ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c CEA SACLAY   (France)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HODGKIN DISEASE; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

DIFFUSION MAGNETIC RESONANCE IMAGING; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84929318686     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.2015140145     Document Type: Article

References (62)

1. Cheson BD, Horning SJ, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI-sponsored International Working Group. J Clin Oncol 1999;17(4):1244–1253.
2. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5):579–586.
3. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fuoro-d-glucose (FDG) PET in nodal staging. Radiology 1997;203(3): 795–800.
4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5):571–578.
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–3068.
6. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32(27):3048–3058.
7. King AD, Ahuja AT, Yeung DK, et al. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 2007;245(3):806–813.
8. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2009;72(3):381–387.
9. Wu X, Pertovaara H, Dastidar P, et al. ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study. Eur J Radiol 2013;82(4):e158–e164. doi:10.1016/j.ejrad.2012.11.021.Published December 18, 2012. Accessed February 7, 2015.
10. van Ufford HM, Kwee TC, Beek FJ, et al. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol 2011;196(3):662–669.
11. Abdulqadhr G, Molin D, Aström G, et al. Whole-body diffusion-weighted imaging compared with FDG-PET/ CT in staging of lymphoma patients. Acta Radiol 2011;52(2):173–180.
12. Lin C, Luciani A, Itti E, et al. Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. Cancer Imaging 2012;12(2):403–408.
13. Mayerhoefer ME, Karanikas G, Kletter K, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 2014;20(11): 2984–2993.
14. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010;20(8):2027–2038.
15. Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol 2011;46(5):341–349.
16. Chen Y, Zhong J, Wu H, Chen N. The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 2012;30(2):165–170.
17. Wu X, Nerisho S, Dastidar P, et al. Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma: a whole-body MRI and diffusion-weighted imaging study. NMR Biomed 2013;26(9):1186–1194.
18. Littooij AS, Kwee TC, Barber I, et al. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT–based reference standard. Eur Radiol 2014;24(5):1153–1165.
19. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622–1635.
20. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102–125.
21. Huang MQ, Pickup S, Nelson DS, et al. Monitoring response to chemotherapy of non-Hodgkin’s lymphoma xenografts by T2-weighted and diffusion-weighted MRI. NMR Biomed 2008;21(10):1021–1029.
22. Le Bihan D. Molecular diffusion nuclear magnetic resonance imaging. Magn Reson Q 1991;7(1):1–30.
23. Le Bihan D, Turner R, Moonen CT, Pekar J. Imaging of diffusion and microcirculation with gradient sensitization: design, strategy, and significance. J Magn Reson Imaging 1991;1(1):7–28.
24. Dijkstra H, Baron P, Kappert P, Oudkerk M, Sijens PE. Effects of microperfusion in hepatic diffusion weighted imaging. Eur Radiol 2012;22(4):891–899.
25. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 2008;18(9): 1937–1952.
26. Poustchi-Amin M, Mirowitz SA, Brown JJ, McKinstry RC, Li T. Principles and applications of echo-planar imaging: a review for the general radiologist. RadioGraphics 2001;21(3):767–779.
27. Malayeri AA, El Khouli RH, Zaheer A, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. RadioGraphics 2011; 31(6):1773–1791.
28. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6(1):135–143.
29. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003;45(3):169–184.
30. Chavhan GB, Babyn PS. Whole-body MR imaging in children: principles, technique, current applications, and future directions. RadioGraphics 2011;31(6):1757–1772.
31. Takahara T, Kwee T, Kibune S, et al. Whole-body MRI using a sliding table and repositioning surface coil approach. Eur Radiol 2010;20(6):1366–1373.
32. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005;4(4):175–186.
33. Choi JS, Kim MJ, Chung YE, et al. Comparison of breathhold, navigator-triggered, and free-breathing diffusion-weighted MRI for focal hepatic lesions. J Magn Reson Imaging 2013;38 (1):109–118.
34. Taouli B, Sandberg A, Stemmer A, et al. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging 2009;30 (3):561–568.
35. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700–718.
36. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009;44(10):683–690.
37. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254(1):47–66.
38. Okada Y, Ohtomo K, Kiryu S, Sasaki Y. Breath-hold T2-weighted MRI of hepatic tumors: value of echo planar imaging with diffusion-sensitizing gradient. J Comput Assist Tomogr 1998;22(3):364–371.
39. Bruegel M, Gaa J, Waldt S, et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and fve T2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008;191(5): 1421–1429.
40. Coenegrachts K, Delanote J, Ter Beek L, et al. Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2-weighted turbo spin echo techniques. Br J Radiol 2007;80(955):524–531.
41. Hwang S, Panicek DM. Magnetic resonance imaging of bone marrow in oncology. II. Skeletal Radiol 2007;36(11): 1017–1027.
42. Schellinger D, Lin CS, Fertikh D, Lauerman WC, Henderson F, Davis B. Normal lumbar vertebrae: anatomic, age, and sex variance in subjects at proton MR spectroscopy—initial experience. Aging Male 2000;3(3):157–158.
43. Messiou C, Collins DJ, Morgan VA, Desouza NM. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 2011;21(8):1713–1718.
44. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scin-tigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010; 39(4):333–343.
45. Kostakoglu L, Cheson BD. State-of-the-art research on lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response. Front Oncol 2013;3:e212. doi:10.3389/fonc.2013.00212. Published September 4, 2013. Accessed February 7, 2015.
46. Padhani AR, Koh DM. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011;19(1):181–209.
47. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010;32(1):2–16.
48. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25(26):4104–4109.
49. Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma: a pilot study—comparison with 2-deoxy-2-fuoro-d-glucose-positron emission tomography/computed tomography. NMR Biomed 2011;24(10):1181–1190.
50. De Paepe K, Bevernage C, De Keyzer F, et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging 2013;13:53–62.
51. Horger M, Claussen C, Kramer U, Fenchel M, Lichy M, Kaufmann S. Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity: a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. Eur J Radiol 2014;83(9):1655–1664.
52. Reichardt W, Juettner E, Uhl M, Elverfeldt DV, Kontny U. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest Radiol 2009; 44(5):298–303.
53. Ustaalioglu BB, Seker M, Bilici A, et al. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma. Med Oncol 2011;28(1):258–264.
54. Thoeny HC, De Keyzer F, King AD. Diffusion-weighted MR imaging in the head and neck. Radiology 2012;263(1):19–32.
55. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009;15(3):986–994.
56. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2):213–220.
57. Jung SH, Heo SH, Kim JW, et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012;35(1):110–116.
58. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109–1113.
59. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009;22(1):104–113.
60. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 2006;16(12):2637–2643.
61. Padhani AR, Gogbashian A. Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging 2011;11(Spec No A):S129–S145.
62. Hiwatashi A, Kinoshita T, Moritani T, et al. Hypointensity on diffusion-weighted MRI of the brain related to T2 shortening and susceptibility effects. AJR Am J Roentgenol 2003; 181(6):1705–1709.